Trualt Bioenergy to hold ‘investor meet’ on June 12

Bengaluru based biofuel conglomerate Trualt Bioenergy Limited has announced that it will host a virtual group meeting with analysts and institutional investors on June 12, 2026, to discuss its business performance and future outlook.

The scheduled interaction will involve analysts and institutional investors in a group meeting format. The interaction will take place as part of the InsightX 2026–Choice Virtual Conference, organized by Choice Equity Broking Pvt. Ltd. The session is scheduled from 11:00 a.m. to 12:00 p.m. (IST) and will be conducted online.

According to Trualt, the discussion during the meeting will be strictly limited to publicly available information. Trualt Bioenergy emphasized that no unpublished price-sensitive information will be disclosed, in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015.

Company officials noted that the timing and details of the meeting may be subject to last-minute changes due to unforeseen circumstances on the part of either the company or participating investors.

Trualt Seeks Shareholder Approval for Rs 2,500 Crore Deals

Trualt has also initiated a postal ballot process to seek shareholder approval for material related-party transactions worth up to Rs 2,500 crore with Nirani Sugars Ltd for the financial year 2026–27.

The proposed transactions include the purchase of raw materials valued at up to Rs 2,000 crore and the sale of goods worth up to Rs 500 crore. Trualt stated that these dealings are crucial to ensure a steady supply of essential feedstock such as bagasse, syrup, and molasses, which are key inputs for its ethanol and bioenergy operations.

The resolution also seeks permission to continue existing contracts and enter into new arrangements with Nirani Sugars Limited, a related party, for a tenure of one year. The company emphasized that the agreements are vital for maintaining uninterrupted operations and supporting its bioenergy production chain.

Approval from shareholders is required as the total transaction value exceeds 10% of the company’s annual consolidated turnover, which stood at ₹1,727.51 crore for FY 2025–26.